Vivet Therapeutics
Business Services · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
80 Boulevard Haussmann, Paris, Ile-de-Fr...Phone Number
+33 684755087Website
www.vivet-therapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Vivet Therapeutics
Vivet Therapeutics is a biotechnology company focused on developing transformative gene therapies for patients with rare genetic disorders. Their innovative pipeline includes liver-directed AAV products aimed at conditions such as Cerebrotendinous Xanthomatosis, Progressive Familial Intrahepatic Cholestasis, and Wilson's disease. The company is dedicated to overcoming challenges posed by neutralizing antibodies to expand access to effective therapies. Their target clients include patients with orphan diseases who have limited or no treatment options available.Explore more
Vivet Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vivet Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Vivet Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Vivet Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Vivet Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Vivet Therapeutics
Check if Vivet Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Vivet Therapeutics is spiking on competitors!
Earning: See what the market has to say on Vivet Therapeutics recently announced quarterly report
Click to see if Vivet Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Vivet Therapeutics
Find 3 more new buyers
Company Profile Activity
Activity Insights
Vivet Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Vivet Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Vivet Therapeutics.
Vivet Therapeutics financials insights
Gather financial insights about Vivet Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$40.9M
2024
Other Financing Round
$5.3M
Vivet Therapeutics Tech Stack
A closer look at the technologies used by Vivet Therapeutics
See more technologies
Vivet Therapeutics News & Media
Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024
Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024Vivet Therapeutics Presents Interim Data from its Phase 1/2 GATEWAY Trial for the Treatment of Wilson Disease at EASL Congress 2024
VTX-801 increased ceruloplasmin ferroxidase activity and improved liver histology Encouraging safety and tolerability with no serious adverse events reported PARIS, June 5, 2024 /PRNewswire/ -- Vivet Therapeutics ("Vivet"), a clinical stage biotech company developing novel and...Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease
Dosing of first patient completed in Cohort 2 following Data Monitoring Committee approval to proceed Encouraging safety, tolerability and early pharmacodynamic changes observed in Cohort 1 with lead program VTX-801 PARIS, April 8, 2024 /PRNewswire/ -- Vivet Therapeutics ('Vivet'), a...Vivet Therapeutics Receives EUR 4.9M Financing
Vivet Therapeutics, a Paris, France-based clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic disorders, received EUR 4.9M in funding. The French Government as part of the France Health Innovation Plan 2030 operated by Bpifrance provided the financing. The company intends to use the funds to further develop its gene […] The post Vivet Therapeutics Receives EUR 4.9M Financing appeared first on FinSMEs.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Vivet Therapeutics
Sign Up For FreeTo access detailed company insights
Vivet Therapeutics is a biotechnology company focused on developing transformative gene therapies for patients with rare genetic disorders. Their innovative pipeline includes liver-directed AAV products aimed at conditions such as Cerebrotendinous Xanthomatosis, Progressive Familial Intrahepatic Cholestasis, and Wilson's disease. The company is ded... Read More
